Conflicts of Interest

A “Money Blind” for Research into Maternal-Fetal Medication Risk?

Filed in Conflicts of Interest, Drugs & Devices by on January 16, 2015 0 Comments
A “Money Blind” for Research into Maternal-Fetal Medication Risk?
Share

By Kate Greenwood Cross-Posted at Bill of Health A week ago, the Food and Drug Administration announced the results of a review of the medical literature it conducted in response to “recent reports questioning the safety of prescription and over-the-counter (OTC) pain medicines when used during pregnancy.” The literature, FDA determined, is inconclusive. FDA found […]

Share

Continue Reading »

New Disclosure Law Shines Light on Prescribing Practices

New Disclosure Law Shines Light on Prescribing Practices
Share

By Jordan Paradise This week, the New York Times reported that ophthalmologists who were paid to promote Genentech’s drug Lucentis (ranibizumab) were among the top billers of the drug to federal programs, exceeding the prescribing amounts of more than 75% of their peers.  Lucentis, approved in 2006 by the Food and Drug Administration (FDA), is indicated […]

Share

Continue Reading »

Industry Funding of CME Down, According to ACCME

Industry Funding of CME Down, According to ACCME
Share

When we think about health care reform, we need to remember that we have been attempting reforms through many avenues of myriad parts of our health system.  The IRS revised Form 990 and schedule H in anticipation of the ACA; critics of conflicts of interest have been working on multiple fronts simultaneously.  One of the […]

Share

Continue Reading »

The NIH’s Amended Conflict of Interest Regulations: A New, Weaker Approach to Intellectual Property Interests?

Filed in Conflicts of Interest by on August 24, 2011 0 Comments
The NIH’s Amended Conflict of Interest Regulations:  A New, Weaker Approach to Intellectual Property Interests?
Share

Yesterday, at long last, the National Institutes of Health released the final revisions to its regulations governing financial conflicts of interest on the part of applicants for federal research funds.  And there is good news.  The rule’s sunshine provisions have not, as was feared, been “gutted.”  Grant recipients will have to make their investigators’ financial […]

Share

Continue Reading »

…After the Horse Has Already Left the Barn: FDA Continues to Postpone Conflicts Review Until Studies Are Complete

…After the Horse Has Already Left the Barn:  FDA Continues to Postpone Conflicts Review Until Studies Are Complete
Share

On Tuesday, the Food and Drug Administration released a draft guidance on financial disclosure by clinical investigators, targeted at the investigators themselves, at drug and device companies and others who sponsor clinical trials, and at the agency staff who review the disclosures.  In the draft guidance, which updates an earlier one, the FDA briefly reviews […]

Share

Continue Reading »